An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Summary

This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications